Attached files
| file | filename |
|---|---|
| EX-10.26 - EX-10.26 - Mersana Therapeutics, Inc. | a2232415zex-10_26.htm |
| EX-10.25 - EX-10.25 - Mersana Therapeutics, Inc. | a2232415zex-10_25.htm |
| EX-10.24 - EX-10.24 - Mersana Therapeutics, Inc. | a2232415zex-10_24.htm |
| EX-10.23 - EX-10.23 - Mersana Therapeutics, Inc. | a2232415zex-10_23.htm |
| EX-10.22 - EX-10.22 - Mersana Therapeutics, Inc. | a2232415zex-10_22.htm |
| EX-10.1 - EX-10.1 - Mersana Therapeutics, Inc. | a2232415zex-10_1.htm |
| EX-5.1 - EX-5.1 - Mersana Therapeutics, Inc. | a2232415zex-5_1.htm |
| EX-1.1 - EX-1.1 - Mersana Therapeutics, Inc. | a2232415zex-1_1.htm |
| S-1/A - S-1/A - Mersana Therapeutics, Inc. | a2232415zs-1a.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of independent registered public accounting firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated March 17, 2017 (except Note 14, as to which the date is June 15, 2017) in Amendment No. 1 to the Registration Statement (Form S-1) and the related Prospectus of Mersana Therapeutics, Inc. for the registration of 5,750,000 shares of its common stock.
| /s/ Ernst & Young LLP | ||
Boston, Massachusetts June 15, 2017 |
Consent of independent registered public accounting firm